Inspire Medical Systems, Inc. has developed the world’s first fully implanted neurostimulation device approved by the FDA for the treatment of Obstructive Sleep Apnea (OSA). The Inspire system uses well-established neurostimulation technologies and incorporates a proprietary algorithm that stimulates key airway muscles based on a patient’s unique breathing patterns. Inspire therapy is designed to reduce OSA severity and improve quality of life for patients living with this challenging condition. Inspire therapy works inside your body, and with your natural breathing process. It might be right for you if you have been diagnosed with OSA, and can't use or don't get relief from CPAP/BiPAP. To learn more, please visit us at
Maple Grove, US
85 (est)+4%

Linspire Locations

Maple Grove, US

Linspire Metrics

Linspire Summary

Founding Date


Total Funding

$73 M

Latest funding size

$40 M

Time since last funding

over 2 years


Kleiner Perkins Caufield & Byers, U.S. Venture Partners (USVP), Johnson & Johnson Development Corporation, Medtronic, Synergy Life Science Partner, GDN Holdings, TGap Ventures, Aperture Venture Partners, OrbiMed

Linspire Company Life